QIMR Berghofer Medical Research Institute, Population Health Department, Herston, Brisbane, Q4006, Australia.
Queensland University of Technology (QUT), School of Nursing and Cancer and Palliative Care Outcomes Centre, Kelvin Grove, Brisbane, Q4059, Australia.
BMC Cancer. 2021 Sep 25;21(1):1055. doi: 10.1186/s12885-021-08756-x.
Patient medical out-of-pocket expenses are thought to be rising worldwide yet data describing trends over time is scant. We evaluated trends of out-of-pocket expenses for patients in Australia with one of five major cancers in the first-year after diagnosis.
Participants from the QSKIN Sun and Health prospective cohort Study with a histologically confirmed breast, colorectal, lung, melanoma, or prostate cancer diagnosed between 2011 and 2015 were included (n = 1965). Medicare claims data on out-of-pocket expenses were analysed using a two-part model adjusted for year of diagnosis, health insurance status, age and education level. Fisher price and quantity indexes were also calculated to assess prices and volumes separately.
On average, patients with cancer diagnosed in 2015 spent 70% more out-of-pocket on direct medical expenses than those diagnosed in 2011. Out-of-pocket expenses increased significantly for patients with breast cancer (mean AU$2513 in 2011 to AU$6802 in 2015). Out-of-pocket expenses were higher overall for individuals with private health insurance. For prostate cancer, expenses increased for those without private health insurance over time (mean AU$1586 in 2011 to AU$4748 in 2014) and remained stable for those with private health insurance (AU$4397 in 2011 to AU$5623 in 2015). There were progressive increases in prices and quantities of medical services for patients with melanoma, breast and lung cancer. For all cancers, prices increased for medicines and doctor attendances but fluctuated for other medical services.
Out-of-pocket expenses for patients with cancer have increased substantially over time. Such increases were more pronounced for women with breast cancer and those without private health insurance. Increased out-of-pocket expenses arose from both higher prices and higher volumes of health services but differ by cancer type. Further efforts to monitor patient out-of-pocket costs and prevent health inequities are required.
据认为,全球范围内患者的医疗自付费用正在上升,但有关随时间推移的趋势的数据却很少。我们评估了澳大利亚五种主要癌症之一的患者在诊断后第一年的自付费用趋势。
本研究纳入了 2011 年至 2015 年间确诊为乳腺癌、结直肠癌、肺癌、黑色素瘤或前列腺癌的 QSKIN Sun 和健康前瞻性队列研究的参与者(n=1965)。使用两部分模型分析医疗保险索赔数据,该模型调整了诊断年份、健康保险状况、年龄和教育程度。还计算了 Fisher 价格和数量指数,以分别评估价格和数量。
平均而言,2015 年诊断的癌症患者的直接医疗费用自付额比 2011 年诊断的患者高出 70%。乳腺癌患者的自付费用显著增加(2011 年为 2513 澳元,2015 年为 6802 澳元)。私人医疗保险的个体总体自付费用较高。对于前列腺癌,无私人医疗保险的患者随时间推移费用增加(2011 年为 1586 澳元,2014 年为 4748 澳元),而有私人医疗保险的患者保持稳定(2011 年为 4397 澳元,2015 年为 5623 澳元)。黑色素瘤、乳腺癌和肺癌患者的医疗服务价格和数量均呈递增趋势。对于所有癌症,药品和医生就诊费用增加,但其他医疗服务费用波动。
随着时间的推移,癌症患者的自付费用大幅增加。对于乳腺癌女性患者和无私人医疗保险的患者,增加幅度更为明显。自付费用的增加既来自于更高的价格,也来自于更高的医疗服务量,但因癌症类型而异。需要进一步努力监测患者的自付费用并防止健康不平等。